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Abstract
Purpose To evaluate the usefulness of PET/CT in melanoma
patients with an elevated serum S-100B tumour marker level.
Methods Out of 165 consecutive high-risk melanoma
patients referred for PET/CT imaging, 47 had elevated
(>0.2 μg/l) S-100B serum levels and a contemporaneous
18F-FDG PET/CT scan. PET/CT scans were evaluated for
the presence of metastases. To produce a composite
reference standard, we used cytological, histological, MRI
and PET/CT follow-up findings as well as clinical and
S-100B follow-up.
Results Among the 47 patients with increased S-100B
levels, PET/CT correctly identified metastases in 38 (30
distant metastases and eight lymph node metastases). In one
patient with cervical lymph node metastases, PET/CT was
negative. Eight patients had no metastases and PET/CT
correctly excluded metastases in all of them. Overall
sensitivity for metastases was 97% (38/39), specificity
100% (8/8) and accuracy 98% (46/47). S-100B was
significantly higher in patients with distant metastases
(mean 1.93 μg/l, range 0.3–14.3 μg/l) than in patients with
lymph node metastases (mean 0.49 μg/l, range 0.3–1.6 μg/l,
p=0.003) or patients without metastases (mean 0.625 μg/l,
range 0.3–2.6 μg/l, p=0.007). However, 6 of 14 patients
with a tumour marker level of 0.3 μg/l had no metastases.
Conclusion In melanoma patients with elevated S-100B
tumour marker levels, FDG-PET/CT accurately identifies
lymph node or distant metastases and reliably excludes
metastases. Because of the significant number of false
positive S-100B tumour marker determinations (17%), we
recommend repetition of tumour marker measurements if
elevated S-100B levels occur before extensive imaging is
used.
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Introduction
18F-fluorodeoxyglucose positron emission tomography
(FDG-PET) is increasingly used to image patients with
melanoma [1]. Recent publications have demonstrated that
FDG-PET/CT has a high accuracy for N- and M-staging in
melanoma patients and is superior to PET alone, CT alone
or conventional imaging methods [2, 3]. Because FDG-
PET/CT is still a relatively expensive technique with limited
availability, it is not practicable to use PET/CT as a screening
tool in all melanoma patients. Thus, it is very important to
identify groups of patients and clinical situations where PET/
CT has a diagnostic and therapeutic impact.
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Long survival of patients with malignant melanoma has
been reported after surgery of regional lymph node
metastases or solitary distant metastases. In many institu-
tions, patients with multiple distant metastases are included
in clinical trials and treated with immuno-chemotherapy
[4]. Thus, accurate staging of melanoma patients with exact
localisation of metastases is crucial for therapy planning.
Serum S-100B has been reported to be a reliable tumour
marker in melanoma, reflecting the tumour burden [5], and
it seems to be useful in monitoring therapy [6, 7]. Further, it
has been shown that S-100B can be used as a prognostic
marker in melanoma patients [8–12]. As demonstrated in
colon cancer and prostate cancer, PET imaging can be very
helpful in localising recurrences in patients with elevated or
increasing tumour marker levels [13–16].
The aim of this study was therefore to assess the value of
FDG-PET/CT in melanoma patients with elevated
(>0.2 μg/l) S-100B tumour marker levels.
Materials and methods
Patients
Our institution is a teaching and tertiary care hospital and a
major referral site for patients with malignant melanoma.
We received approval from our institutional review
board to undertake this study.
One hundred and sixty-five consecutive melanoma
patients followed up according to updated Swiss melanoma
guidelines [17] were referred for FDG-PET/CT imaging
between January 2005 and January 2006. Retrospectively,
from among this population, 47 patients (27 women, 20
men; mean age 58.4 years, range 20–83 years) who fulfilled
the following criteria were selected: (1) diagnosis of high-
risk melanoma (Breslow tumour thickness >4 mm, Clark
level III or IV or known resected metastases in the case
history); (2) elevated S-100B levels (>0.2 μg/l); (3) FDG-
PET/CT and S-100B measurement within an interval of not
more than 2 weeks; (4) no treatment between PET/CT and
tumour marker measurement; (5) no systemic therapy before
the PET/CT investigation. Informed consent was obtained
from all patients before they were investigated.
Determination of S-100B
The determination of serum S-100B was done with a
commercially available immunoassay (ELISA) kit (Sangtec
100 ELISA, Dia Sorin Inc, Stillwater, NM, USA) according
to the manufacturer’s instructions. Cut-off was determined
to be 0.2 μg/l (the 95th percentile of blood donor samples).
Values ≥0.3 μg/l were considered suspicious for melanoma
metastases. The detection limit is 0.03 μl/l (BO+3SD).
Intra-assay and inter-assay precision was estimated by
analysis of variance (ANOVA). The within-run and total
imprecision is <10%. The evaluation of S-100B was
introduced in our clinic in 1992.
PET/CT imaging
All the data were acquired on a combined PET/CT in-line
system (Discovery LS or Discovery ST, GE Health Systems,
Milwaukee, WI). These dedicated systems integrate a PET
scanner (GE Advance Nxi, GE Health Systems, Milwaukee,
WI) with a multislice helical CT (LightSpeed plus or Light-
speed 16; GE Health Systems, Milwaukee,WI) and permit the
acquisition of co-registered CTand PET images in one session.
Patients fasted for at least 4 h prior to the scanning,
which started 60 min after the injection of 370–400 MBq of
18F-FDG. All patients were tested for a normal glucose
level [range 80–120 mg/dl (4.4–6.7 mmol/l)] before scan-
ning. Patients with elevated glucose levels were rescheduled
and scanned with normal glucose levels. Oral CT contrast
agent (Micropaque Scanner, Guerbet AG, Aulnay-sous-bois,
France) was given 15 min before the injection of 18F-FDG.
Patients were examined in the supine position. No
intravenous contrast agent was given. Initially, the CT scan
was acquired starting from the level of the head using the
following parameters: 40 mAs, 140 kV, 0.5 s/tube rotation,
slice thickness 4.25 mm, scan length 867 mm, data
acquisition time 22.5 s. The CT scan was acquired during
breath holding in the normal expiratory position.
Immediately following the CT acquisition, a PET emis-
sion scan was acquired with an acquisition time of 3 min per
cradle position with a one-slice overlap in 2D mode (matrix
128×128). The eight to nine cradle positions starting from
the head to the knees resulted in an acquisition time of
approximately 24–27 min. In the patients with primary
tumours of the lower extremities, the scanning of the lower
legs was added. The CT data were used for attenuation
correction of the PET datasets and the images were
reconstructed using a standard iterative algorithm (OSEM).
The acquired images were viewed with software providing
multiplanar reformatted images of PET alone, CT alone and
fused PET/CT with linked cursors using a Xeleris worksta-
tion (GE Health Systems, Milwaukee, WI).
PET/CT imaging was performed according to the
recently published procedure guideline for tumour imaging
with 18F-FDG PET/CT version 1.0 [18].
PET/CT interpretation
The images were reviewed and analysed by two experienced
nuclear radiology physicians without knowledge of the results
of other imaging studies or the level of serum S-100B. A
consensus was reached on every observed lesion. The PET
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Table 1 Patient characteristics, S-100B values and results of PET/CT imaging
Pat. no. Gender Age
(yrs)
Breslow
thickness (mm)
Serum
S-100B (μg/l)
PET/CT Ref.
standard
Therapy Localisation of mets.a
1 F 49 ? 0.3 No mets No mets No –
2 M 45 3.00 0.3 No mets No mets No –
3 F 52 1.50 0.3 No mets No mets No –
4 F 83 ? 0.3 No mets No mets No –
5 M 67 2.75 0.3 No mets No mets No –
6 F 43 ? 0.3 No mets No mets No –
7 F 33 1.90 0.6 No mets No mets No –
8 F 74 5.50 2.6 No mets No mets No –
9 F 68 1.20 0.3 LN mets LN mets OP LN (iliac)
10 M 36 ? 0.3 LN mets LN mets OP LN (axilla)
11 F 67 4.00 0.3 LN mets LN mets OP LN (inguinal)
12 F 73 3.50 0.3 LN mets LN mets OP LN (inguina)
13 F 59 ? 0.3 LN mets LN mets OP LN (inguinal)
14 M 72 5.80 0.3 LN mets LN mets OP LN (cervical)
15 F 77 4.60 0.4 No mets LN mets OP LN (cervical), probable bone met
16 M 69 1.10 0.6 LN mets LN mets OP LN (axilla)
17 F 58 3.30 1.6 LN mets LN mets OP LN (inguinal and popliteal)
18 M 73 8.00 0.3 Dist mets Dist mets Chemo Dist LN
19 M 50 4.30 0.3 Dist mets Dist mets Chemo Liver, bone, LN
20 M 66 3.70 0.4 Dist mets Dist mets Chemo Lung, adrenal, soft tissue, dist LN
21 M 70 3.45 0.4 Dist mets Dist mets Chemo Liver
22 M 59 ? 0.5 Dist mets Dist mets OP Bone (clavicle)
23 F 49 1.80 0.5 Dist mets Dist mets Chemo Lung, bone, dist LN, soft tissue
24 M 42 3.65 0.5 Dist mets Dist mets Chemo Lung, liver, soft tissue
25 F 47 1.20 0.5 Dist mets Dist mets Chemo LN (inguinal), lung
26 F 79 ? 0.5 Dist mets Dist mets Chemo Soft tissue
27 F 68 11.00 0.5 Dist mets Dist mets Chemo Lung, liver
28 F 46 1.70 0.6 Dist mets Dist mets Chemo Lung, dist LN
29 F 81 2.50 0.6 Dist mets Dist mets Chemo Lung
30 M 71 5.30 0.6 Dist mets Dist mets Chemo Lung, liver, soft tissue, dist LN
31 F 43 2.75 0.6 Dist mets Dist mets Chemo Liver, bone, LN
32 F 20 2.10 0.6 Dist mets Dist mets Chemo Liver, dist LN
33 M 66 4.50 0.6 Dist mets Dist mets Chemo Lung, soft tissue
34 F 49 1.02 0.7 Dist mets Dist mets Chemo Soft tissue, dist LN
35 F 70 8.00 0.8 Dist mets Dist mets OP Intestine, dist LN
36 F 72 15.00 0.8 Dist mets Dist mets Chemo Soft tissue
37 M 51 7.50 0.8 Dist mets Dist mets Chemo Liver, lung, bone
38 M 56 6.00 0.9 Dist mets Dist mets Chemo Liver, soft tissue, dist LN
39 M 53 ? 0.9 Dist mets Dist mets Chemo, RT LN (axilla), dist LN
40 F 47 1.30 0.9 Dist mets Dist mets Chemo Lung, liver, brain
41 M 59 3.50 1.3 Dist mets Dist mets Chemo Lung
42 F 41 6.50 1.7 Dist mets Dist mets Chemo Lung, liver, adrenal, soft tissue
43 M 83 3.90 2.0 Dist mets Dist mets Chemo Lung, soft tissue
44 F 49 0.94 4.2 Dist mets Dist mets Chemo Lung, bone, brain, soft tissue
45 M 42 2.24 7.9 Dist mets Dist mets Chemo Intestine, dist LN
46 M 67 1.40 12.6 Dist mets Dist mets Chemo Lung, liver
47 F 52 ? 14.3 Dist mets Dist mets Chemo Liver, adrenal, dist LN
? Depth of the primary tumour not known, M male, F female, dist mets distant metastases, LN mets regional lymph node metastases, dist LN
distant lymph node metastases (no regional LN mets), OP operative resection, Chemo chemotherapy, RT radiotherapy
a According to the reference standard
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images and the corresponding CT images of the PET/CTstudy
were analysed for the presence and nature of focal lesions with
elevated FDG uptake. For all of the patients, the attenuation-
corrected PET images were analysed. Lesions were interpreted
as metastases if the FDG uptake was clearly greater than
background. If a focal FDG-active lesion was detected, the
exact anatomical localisation was determined on the fused
PET/CT images. Lesions with 18F-FDG uptake in physiolog-
ical sites or benign variants, e.g. muscles, brown fatty tissue
or pulmonary infiltrations, were determined as benign. CT
images were additionally analysed concerning FDG-inactive
soft tissue dense lesions without calcifications, especially in
the lungs and subcutaneous fatty tissue. Lesions suspicious
for metastases according to the established morphological
CT criteria known from diagnostic radiology were also
diagnosed as metastases.
Reference standard
Lymph node or distant metastases were confirmed by a
histopathological or cytological examination or other
imaging modalities such as magnetic resonance imaging
(MRI), PET/CT follow-up and clinical follow-up for a
minimum of 6 months (range 6–18 months in all patients),
Fig. 1 A 77-year-old female
patient with high-risk melano-
ma and elevated serum S-100B
(0.4 μg/l). a MIP image and
b axial images through the neck
without evidence of metastases.
There is elevated FDG uptake in
both shoulders and the right
patella (arrows) due to osteoar-
thritis. Contamination is present
at the injection site of the left
elbow (arrowhead). c MIP
image 6 months later with
increased FDG uptake in the
cervical lymph nodes on the left
side (arrow) and in the thoracic
spine (arrowhead). d Axial
images demonstrating that the
elevated FDG uptake belongs to
a level II lymph node on the left
side (arrowhead). The cervical
lymph node metastases were
resected and confirmed histo-
logically. MRI of the spine was
inconclusive as it showed a
small lesion in the transverse
process
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including follow-up measurement of the serum S-100B. A
false negative PET/CT diagnosis was determined if another
imaging method (superior for the investigated region, such
as brain MRI) showed metastases or if clinical findings
raised the suspicion of metastases which were then proven
by histology. A false positive PET/CT diagnosis was
determined if histology of the lesion and/or clinical and
PET/CT follow-up (complete disappearance of focal FDG-
active lesion without therapy) ruled out metastases. FDG-
negative, non-calcified lesions (for example in the lung)
were determined as false positive if there was no change in
lesion number or size on the follow-up PET/CT examina-
tions 3 or 6 months later and no clinical suspicion of
metastases arose >6 months after the scan.
Statistical analysis
The recorded data were entered into a worksheet (Excel;
Microsoft, Redmond, Washington). Data analysis was
performed on a patient basis. SPSS (version 11; 2002;
SPSS Inc.) was used for statistical analysis. Sensitivity,
specificity and accuracy are presented with exact 95%
confidence intervals (Scientific Tables by Geigy, Volume on
statistics, 8th edition, Basle 1980). The Mann-Whitney test
with Bonferroni correction was used to assess statistical
differences in serum S-100B values in patients without
metastases, with regional lymph node metastases and with
distant metastases. Thus, p<0.017 was considered to
indicate a significant difference.
Fig. 1 (continued)
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Results
Patient characteristics are summarised in Table 1. Thirty
(64%) of the 47 patients had distant metastases, nine (19%)
had regional lymph node metastases and eight (17%)
patients had no metastases. Of patients with distant
metastases, 20 had their findings confirmed by histology,
four by cytology and six by MRI, PET/CT follow-up and
clinical follow-up. All nine patients with regional lymph
node metastases had their diagnoses confirmed histologi-
cally following surgical resection.
PET/CT correctly detected distant metastases in all 30
patients. PET/CT identified lymph node metastases in eight
patients and missed multiple level II and III cervical lymph
node metastases and a probable vertebral spinal metastasis
in one patient (no. 15., Fig. 1). Eight patients had no
metastases and PET/CT correctly excluded metastases in all
these patients. Overall sensitivity for metastases was 97%
(38/39) [95% CI, 87–100%], specificity 100% (8/8) [63–
100%] and accuracy 98% (46/47) [89–100%]. Serum S-
100B was significantly higher in patients with distant
metastases (mean 1.93 μg/l, range 0.3–14.3 μg/l) than in
patients with regional lymph node metastases (mean 0.49,
range 0.3–1.6, p=0.003) or patients without metastases
(mean 0.625, range 0.3–2.6, p=0.007); however, there was
considerable overlap between each of the subgroups. There
was no statistical significant difference in S-100B values
between patients with lymph node metastases and patients
without metastases (p=0.86).
Six (42.9%) of the 14 patients with a weakly elevated
tumour marker of 0.3 μg/l had no metastases, six (42.9%)
had regional lymph node metastases and two (14.3%) had
distant metastases. An example of a patient with distant
metastases and elevated S-100B is shown in Fig. 2.
Fig. 2 A 70-year-old female
patient with high-risk melano-
ma and elevated S-100B
(0.8 μg/l). a MIP image dem-
onstrating two focal FDG-active
lesions in the abdomen
(arrows). b On the axial images
one FDG-active lesion (arrow-
head) corresponds to wall
thickening (arrow) in the small
intestine. The lesion was
resected and histology con-
firmed the PET/CT diagnosis of
small intestine metastases
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Eight patients had “false positive” S-100B tumour markers
(Table 2). In three patients (nos. 5, 6 and 7) with S-100B
values of 0.3–0.6 μg/l we found a history of brain operation
for melanoma metastases (2 weeks, 6 months and 8 years
previously). One patient (no. 8) with a normal S-100B value
6 months prior to the study showed an increase in S-100B to
2.6 μg/l without clinical evidence of metastases. PET/CT at
the timepoint of the elevated tumour marker and PET/CT
follow-up investigations after 2, 6 and 18 months were
normal. S-100B levels measured 2 weeks and 6 and
18 months after the pathological value were normal (0.1–
0.2 μg/l). Similarly, in the remaining four patients (nos. 1–4)
we found no explanation for an elevated S-100B value in the
history. The follow-up S-100B measurements, PET/CT scans
and clinical investigations remained without evidence of
metastases. In one patient (no. 37) with an S-100B of 0.8 μg/l,
PET/CTonly detected a solitary metastasis in a vertebral body
of the thoracic spine (Fig. 3). MRI and contrast-enhanced CT,
performed in the following week, showed disseminated
small liver and bone metastases, so that PET/CT as correct in
the diagnosis of distant metastasis but severely underesti-
mated the extent of metastases. Twelve patients had lung
metastases. Lung metastases were FDG active in eight
patients and FDG inactive in four patients. In these four
patients the lung metastases were only detected by the
additional interpretation of the lung window of the CT
examination. Two patients had brain metastases. They were
detectable in both patients with PET/CT because of elevated
FDG uptake compared with normal brain tissue in one
patient and because of additional bleeding in the other
patient. Additionally in both patients perifocal vasogenic
oedema was present in CT images.
Discussion
To our knowledge, this is the first study to describe the
value of integrated PET/CT imaging in the follow-up of
melanoma patients with elevated S-100B tumour marker
levels. The results demonstrate that FDG-PET/CT is very
useful in this selected group of melanoma patients with a
high risk for the presence of metastases. FDG-PET/CT
reliably discriminates between patients with distant metas-
tases, which are usually treated with chemotherapy, and
patients with regional lymph node metastases, which are
often treated by surgery. If an S-100B level of 0.3 μg/l or
more is considered pathological, there is a significant
number of patients with false positive S-100B. FDG-PET/
CT excluded metastases correctly in all of these patients.
One of our study patients with a slightly elevated S-100B
level (0.4 μg/l) had a normal PET/CT scan. Cytologically
proven cervical lymph metastases were diagnosed 5 months
after the FDG-PET/CT examination. This situation was
interpreted as a false negative PET/CT diagnosis. It has
been shown in several studies that FDG-PET/CT has
limitations in the detection of microscopic lymph node
metastases. FDG-PET was compared with sentinel node
biopsy in a prospective study. The sensitivity of FDG-PET
was 16.7% and the specificity, 95.8%. [19]. Thus, sentinel
lymph node biopsy remains the standard and is clearly
superior to FDG-PET(/CT) in detecting regional lymph
node metastases [20, 21].
FDG-PET reliably detects lymph node tumour deposits
with a volume larger than 80 mm3, but sensitivity falls
rapidly below this value because of partial volume effects
that reduce the FDG signal [22]. All lymph node metastases
Table 2 History and follow-up of eight patients with false positive S-100B tumour marker levels
Pat.
no.
Initial serum
S-100B (μg/l)
History Serum S-100B (μg/l)
at follow-up
PET/CT follow-up Clinical follow-up
1 0.3 Inconspicuous 0.2/3 mo; 0.2/5 mo No mets after 6 mo No evidence of mets after 8 months
2 0.3 Inconspicuous 0.0/3 mo; 0.0 /12 mo No mets after 12 mo No evidence of mets after 12 months
3 0.3 Inconspicuous 0.2/7 mo No No evidence of mets after 12 months
4 0.3 Inconspicuous 0.2/5 mo; 0.2/15 mo;
0.1/27 mo
No mets after 6 mo No evidence of mets after 27 months
5 0.3 2 wk after resection
of brain metastases
No No Died 6 wk after PET due to postop.
infection; mets cannot be excluded
6 0.3 8 yr after resection
of brain metastases
0.1/6 mo;
0.2/12 mo;
0.1/18 mo
No mets after 6 mo/
18 mo
No evidence of mets after 18 months
7 0.6 6 mo after resection
of brain metastases
0.1/6 wk; 0.1/3 mo; 0.0/6 mo;
0.1/12 mo; 0.1/24 mo
No mets after 6 mo/
12 mo/18 mo/
24 mo
No evidence of mets
after 24 months
8 2.6 Inconspicuous 0.2/2 wk; 0.1/6 mo;
0.2/18 mo
No mets after 2 mo/
6 mo/18 mo
No evidence of mets after 24 months
wk weeks, mo months, yr years, mets metastases
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detected with PET/CT in our patients measured more than
6 mm. We know from other studies that some patients with
microscopic or occult lymph node metastases have normal
S-100B values. Reinhardt et al. reported that 8 of 11
patients with lymph node metastases and no distant
metastases had normal S-100B values (all 0.1 μg/l) and
only three had elevated levels (0.3, 0.9 and 1.6 μg/l). By
contrast, all 13 patients with proven distant metastases had
elevated S-100B values (range 0.3–23 μg/l) [23]. Bearing
in mind the hypothesis that S-100B values are related to
total tumour burden, it seems reasonable that if lymph node
metastases lead to an elevated S-100B, the chance is very
high that they will be detectable with FDG-PET/CT.
We also found a considerable number of false positive
S-100B tumour marker determinations (17%; 95% CI, 6%–
28%). There are various possible reasons for a false
positive S-100B value: elevated S-100B levels have been
observed after head trauma, subarachnoidal haemorrhage
and stroke. It has been reported that S-100B reflects the
extent of injury and the outcome of brain-injured patients
[24, 25]. Furthermore, it indicates blood-brain barrier
dysfunction [26, 27]. Molina et al. measured S-100B levels
Fig. 3 A 51-year-old male pa-
tient with high-risk melanoma
and elevated S-100B (0.8 μg/l).
PET (MIP image, a) and axial
fused PET/CT image (b) show a
solitary bone lesion in a thoracic
vertebral body (arrow). MRI
(sagittal contrast-enhanced fat-
saturated image, c) shows mul-
tiple disseminated enhancing
bone metastases (arrows) in the
whole spine. CT (axial contrast-
enhanced image, d) detects dis-
seminated small liver metastases
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in healthy people, patients with benign diseases and patients
with malignancies, including patients with locoregional
disease and advance diseases. All of the healthy people had
normal S-100B values. Slightly elevated S-100B concen-
trations were found in 25% of individuals with benign
diseases. Significantly higher S-100B serum levels were
found in patients with liver cirrhosis or renal failure.
Pathological S-100B serum levels were found in 22.5% of
individuals with malignancies. The highest S-100B concen-
trations were found in patients with malignant melanomas.
They concluded that “S-100 is a useful marker for melanoma,
but abnormal levels of this tumour marker may be found in
benign and malignant diseases associated with liver or renal
injury” [26]. In three of our eight patients with false positive
S-100B values we found brain operations in their past
history. In one patient a melanoma brain metastasis had been
resected 2 weeks before an S-100B level of 0.3 μg/l was
measured. This patient died 6 weeks after the PET/CT due to
postoperative infected subdural haematoma. In two other
patients the brain operations could not explain the elevated
S-100B level because the operations had been performed
6 months and 8 years previously. In the latter two patients no
brain or other metastases developed at follow-up. In five of
the eight patients with “false positive” tumour marker levels
we found no explanation in the history or follow-up.
It is well known that PET has poor sensitivity in
detecting brain metastases owing to the high physiological
FDG uptake in the normal brain [28]. MRI is the imaging
gold standard in the detection of brain metastases [29].
Among our patients we had no case in which PET/CT
missed brain metastases; however, in patients with repeat-
edly elevated tumour markers and negative PET(/CT),
additional brain MRI is strongly recommended.
A recently published study compared FDG-PET/CT
imaging for N- and M-staging of 250 consecutive melano-
ma patients with PET alone and CT alone. The accuracy of
PET/CT for M-staging was significantly higher than that of
PET alone and CT alone (98% vs 93% and 84%). A change
of treatment according to PET/CT findings occurred in 121
of the patients (48.4%). Interestingly, the authors pointed
out that the most significant advantage of PET/CT in
comparison to the single modalities PET and CT was
observed in the detection of visceral metastases [2].
Performance of PET/CT in this study corresponds quite
well with our results (overall accuracy 97.8%). Although
we report a 100% specificity in this paper, we want to point
out that false positive cases occur in our daily routine
outside of this presented patient population.
The effect of chemotherapy in stage IV melanoma
patients is still disappointing [30, 31]. Many patients with
metastases are included in clinical trials where therapy
response has to be assessed [32]. The data of Henze et al.
support the value of serum S-100B as a clinical marker for
monitoring response of metastatic melanoma during sys-
temic therapies [6] but there are clear limitations in its
sensitivity and specificity. We think that FDG-PET/CT may
be very useful in therapy assessment of melanoma patients
in a similar way to its use in patients with oesophageal,
lung and head and neck cancers, but data are still very
limited. In an ongoing study we plan to evaluate the
behaviour of S-100B, standardised uptake value and total
lesion glycolysis in stage IV melanoma patients treated
with chemotherapy.
Our study has some limitations. As in all studies
evaluating the accuracy of staging, the establishment of a
standard of reference with which the method can be
compared is difficult, because we cannot ethically justify
obtaining histological proof of the diagnosis for all lesions
identified. Nevertheless, we exercised great caution in
establishing our standard of reference by using histopath-
ological or cytological confirmation of the suspected
metastases in 33/39 of patients (24 of 30 patients with
distant metastases and all nine patients with lymph node
metastases) and by confirming the findings with another
structural imaging modality or with PET/CT and clinical
follow-up.
We did not investigate whether the outcome of the
patients correlated with the S-100B level. We know from
other publications that there is a strong association between
S-100B level and overall survival and that S-100B can be
used as a prognostic marker [8, 9, 11, 12, 33]. Whether
FDG-PET/CT can be used as an independent prognostic
factor has to be investigated in further studies.
This is a retrospective study and has a selection bias
because only patients with elevated S-100B values were
included. We chose this selection because we were
interested in the value of PET/CT in this particular clinical
situation.
To avoid unnecessary PET/CT investigations in patients
with false positive S-100B values, like other authors we
recommend repeating the S-100B determination after 2–4
weeks if it is initially elevated in the absence of clinical
evidence of metastases [34]. Further, we recommend that
the S-100B measurements should be performed in the
same laboratory always using the same method, thereby
avoiding the bias associated with use of different assays
[35]. Our results confirm that S-100B is not useful in
melanoma patients after brain operation or trauma.
Because FDG-PET/CT has been proven to be superior to
PET alone or conventional imaging methods like CT or
ultrasound [2, 36], we recommend FDG-PET/CT as the
first imaging method in patients with repeatedly elevated
S-100B.
In conclusion, our results indicate that integrated PET/
CT imaging has a significant value in triaging melanoma
patients with elevated S-100B tumour marker levels.
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